Order results by:
Issue | Title | |
Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
"... for 1 QALY, and for standard therapy it was 179 552,2 RUB for 1 QALY. Treatment by intraosseous ..." | ||
Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
N. Z. Musina, V. K. Fedyaeva | ||
"... This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia ..." | ||
Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
A. Yu. Kulikov, I. V. Novikov | ||
"... and effectiveness in terms of QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combination ..." | ||
Vol 6, No 3 (2013) | METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES | Abstract similar documents |
R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze | ||
Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
"... , which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow ..." | ||
Vol 12, No 3 (2019) | Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics | Abstract PDF (Eng) similar documents |
S. V. Ponomarenko | ||
Vol 6, No 2 (2013) | PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION | Abstract similar documents |
V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina | ||
"... (QALY) is growing, which makes it advisable to use ART in health care on larger scale. ..." | ||
Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
"... prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling ..." | ||
Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
"... , improves the quality of life of patients, adding 0.73 QALY per patient. Modelling suggests ..." | ||
Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
"... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..." | ||
Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
"... and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year ..." | ||
Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
"... добавленных лет жизни с качеством 100% (QALY). Из расчета лечения одного пациента, страдающего ХФ ХМЛ, на ..." | ||
Vol 11, No 3 (2018) | Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review | Abstract similar documents |
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin | ||
"... (QALYs), adverse events, and other clinical outcomes. The search for the relevant information ..." | ||
Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
"... + alloSCT vs Ch ± RT per life year (LY) and quality-adjusted life year (QALY) was calculated. In the second ..." | ||
1 - 14 of 14 Items |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)